Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Elizabeth J. Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J. Müller, Henry M. Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan Tsong Chen, Bruce C. Carleton, Alfred L. George, Taisei Mushiroda, Teri Klein, Roseann S. Gammal, Munir Pirmohamed*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

104 Scopus citations

Abstract

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

Original languageEnglish (US)
Pages (from-to)574-581
Number of pages8
JournalClinical pharmacology and therapeutics
Volume103
Issue number4
DOIs
StatePublished - Apr 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update'. Together they form a unique fingerprint.

Cite this